AveXis Turns to Catalent’s Paragon for Additional Gene Therapy Manufacturing Capacity

Originally Published in GEN Engineering and Biotechnology News
By Alex Philippidis– July 16, 20190

AveXis, a Novartis Company, will use Catalent-owned Paragon Gene Therapy’s new commercial manufacturing center near Baltimore-Washington International Airport as an additional manufacturing site for its spinal muscular atrophy (SMA) gene therapy Zolgensma^®(onasemnogene abeparvovec-xioi), Catalent Biologics said today.

Catalent and AveXis have signed a long-term strategic agreement whose value was not disclosed. AveXis will use dedicated manufacturing space within Paragon’s Harmans, MD, facility, a 151,000-square-foot former warehouse that Paragon converted into a contract developing and manufacturing site which opened in April.

“We are pleased to add additional manufacturing capacity and technical expertise through this collaboration as we rapidly scale up product production,” Andy Stober, Senior VP of Technical Operations for AveXis, said in a statement. “We look forward to working with Catalent in continued service of the SMA community.”

Catalent said the additional capacity, along with access to its adeno-associated virus (AAV) gene therapy development, manufacturing, and process characterization expertise, will enable AveXis to ensure a stable and consistent supply of Zolgensma as AveXis prepares to launch the gene therapy.

Read The Full Article

The following two tabs change content below.

• Bio
• Latest Posts

Chris Frew

President, CEO at Biobuzz Media & Workforce Genetics

Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.

Latest posts by Chris Frew (see all)

• Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study - November 2, 2021
• Children’s National’s Dr. Kurt Newman Named WBJ’s 2021 CEO of the Year - October 26, 2021
• SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases | Business Wire - October 26, 2021
• Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company | Business Wire - October 21, 2021
• D&D Pharmatech Raises $51M in Series C Financing to Advance Phase 2 Clinical Trials for Neurodegenerative, Fibrotic, and Metabolic Diseases - October 19, 2021